A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with leukocytes

Standard

A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with leukocytes. / Wallis, Stuart; Wolska, Nina; Englert, Hanna; Posner, Mareike; Upadhyay, Abhishek; Renné, Thomas; Eggleston, Ian; Bagby, Stefan; Pula, Giordano.

In: J THROMB HAEMOST, Vol. 20, No. 3, 03.2022, p. 729-741.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Wallis, S, Wolska, N, Englert, H, Posner, M, Upadhyay, A, Renné, T, Eggleston, I, Bagby, S & Pula, G 2022, 'A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with leukocytes', J THROMB HAEMOST, vol. 20, no. 3, pp. 729-741. https://doi.org/10.1111/jth.15613

APA

Wallis, S., Wolska, N., Englert, H., Posner, M., Upadhyay, A., Renné, T., Eggleston, I., Bagby, S., & Pula, G. (2022). A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with leukocytes. J THROMB HAEMOST, 20(3), 729-741. https://doi.org/10.1111/jth.15613

Vancouver

Bibtex

@article{1f89bfb0da1e40d0a111a110f9d63831,
title = "A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with leukocytes",
abstract = "AIMS: P-selectin is a key surface adhesion molecule for the interaction of platelets with leukocytes. We have shown previously that the N-terminal domain of Staphylococcus aureus extracellular fibrinogen-binding protein (Efb) binds to P-selectin and interferes with platelet-leukocyte aggregate formation. Here, we aimed to identify the minimal Efb motif required for binding platelets and to characterize its ability to interfering with the formation of platelet-leukocyte aggregates.METHODS AND RESULTS: Using a library of synthetic peptides, we mapped the platelet-binding site to a continuous 20 amino acid stretch. The peptide Efb68-87 was able to bind to resting and, to a greater extent, thrombin-stimulated platelets in the absence of fibrinogen. Dot blots, pull-down assays and P-selectin glycoprotein ligand-1 (PSGL-1) competitive binding experiments identified P-selectin as the cellular docking site mediating Efb68-87 platelet binding. Accordingly, Efb68-87 did not bind to other blood cells and captured platelets from human whole blood under low shear stress conditions. Efb68-87 did not affect platelet activation as tested by aggregometry, flow cytometry and immunoblotting, but inhibited the formation of platelet-leukocyte aggregates (PLAs). Efb68-87 also interfered with the platelet-dependent stimulation of neutrophil extracellular traps (NETs) formation in vitro.CONCLUSIONS: We have identified Efb68-87 as a novel selective platelet-binding peptide. Efb68-87 binds directly to P-selectin and inhibits interactions of platelets with leukocytes that lead to PLA and NET formation. As PLAs and NETs play a key role in thromboinflammation, Efb68-87 is an exciting candidate for the development of novel selective inhibitors of the proinflammatory activity of platelets.",
author = "Stuart Wallis and Nina Wolska and Hanna Englert and Mareike Posner and Abhishek Upadhyay and Thomas Renn{\'e} and Ian Eggleston and Stefan Bagby and Giordano Pula",
note = "This article is protected by copyright. All rights reserved.",
year = "2022",
month = mar,
doi = "10.1111/jth.15613",
language = "English",
volume = "20",
pages = "729--741",
journal = "J THROMB HAEMOST",
issn = "1538-7933",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - A peptide from the staphylococcal protein Efb binds P-selectin and inhibits the interaction of platelets with leukocytes

AU - Wallis, Stuart

AU - Wolska, Nina

AU - Englert, Hanna

AU - Posner, Mareike

AU - Upadhyay, Abhishek

AU - Renné, Thomas

AU - Eggleston, Ian

AU - Bagby, Stefan

AU - Pula, Giordano

N1 - This article is protected by copyright. All rights reserved.

PY - 2022/3

Y1 - 2022/3

N2 - AIMS: P-selectin is a key surface adhesion molecule for the interaction of platelets with leukocytes. We have shown previously that the N-terminal domain of Staphylococcus aureus extracellular fibrinogen-binding protein (Efb) binds to P-selectin and interferes with platelet-leukocyte aggregate formation. Here, we aimed to identify the minimal Efb motif required for binding platelets and to characterize its ability to interfering with the formation of platelet-leukocyte aggregates.METHODS AND RESULTS: Using a library of synthetic peptides, we mapped the platelet-binding site to a continuous 20 amino acid stretch. The peptide Efb68-87 was able to bind to resting and, to a greater extent, thrombin-stimulated platelets in the absence of fibrinogen. Dot blots, pull-down assays and P-selectin glycoprotein ligand-1 (PSGL-1) competitive binding experiments identified P-selectin as the cellular docking site mediating Efb68-87 platelet binding. Accordingly, Efb68-87 did not bind to other blood cells and captured platelets from human whole blood under low shear stress conditions. Efb68-87 did not affect platelet activation as tested by aggregometry, flow cytometry and immunoblotting, but inhibited the formation of platelet-leukocyte aggregates (PLAs). Efb68-87 also interfered with the platelet-dependent stimulation of neutrophil extracellular traps (NETs) formation in vitro.CONCLUSIONS: We have identified Efb68-87 as a novel selective platelet-binding peptide. Efb68-87 binds directly to P-selectin and inhibits interactions of platelets with leukocytes that lead to PLA and NET formation. As PLAs and NETs play a key role in thromboinflammation, Efb68-87 is an exciting candidate for the development of novel selective inhibitors of the proinflammatory activity of platelets.

AB - AIMS: P-selectin is a key surface adhesion molecule for the interaction of platelets with leukocytes. We have shown previously that the N-terminal domain of Staphylococcus aureus extracellular fibrinogen-binding protein (Efb) binds to P-selectin and interferes with platelet-leukocyte aggregate formation. Here, we aimed to identify the minimal Efb motif required for binding platelets and to characterize its ability to interfering with the formation of platelet-leukocyte aggregates.METHODS AND RESULTS: Using a library of synthetic peptides, we mapped the platelet-binding site to a continuous 20 amino acid stretch. The peptide Efb68-87 was able to bind to resting and, to a greater extent, thrombin-stimulated platelets in the absence of fibrinogen. Dot blots, pull-down assays and P-selectin glycoprotein ligand-1 (PSGL-1) competitive binding experiments identified P-selectin as the cellular docking site mediating Efb68-87 platelet binding. Accordingly, Efb68-87 did not bind to other blood cells and captured platelets from human whole blood under low shear stress conditions. Efb68-87 did not affect platelet activation as tested by aggregometry, flow cytometry and immunoblotting, but inhibited the formation of platelet-leukocyte aggregates (PLAs). Efb68-87 also interfered with the platelet-dependent stimulation of neutrophil extracellular traps (NETs) formation in vitro.CONCLUSIONS: We have identified Efb68-87 as a novel selective platelet-binding peptide. Efb68-87 binds directly to P-selectin and inhibits interactions of platelets with leukocytes that lead to PLA and NET formation. As PLAs and NETs play a key role in thromboinflammation, Efb68-87 is an exciting candidate for the development of novel selective inhibitors of the proinflammatory activity of platelets.

U2 - 10.1111/jth.15613

DO - 10.1111/jth.15613

M3 - SCORING: Journal article

C2 - 34846792

VL - 20

SP - 729

EP - 741

JO - J THROMB HAEMOST

JF - J THROMB HAEMOST

SN - 1538-7933

IS - 3

ER -